Home Exploration of suitable external quality assessment materials for serum C-peptide measurement
Article
Licensed
Unlicensed Requires Authentication

Exploration of suitable external quality assessment materials for serum C-peptide measurement

  • Yuhang Deng ORCID logo , Chao Zhang , Bingqiong Li , Jing Wang , Jie Zeng , Jiangtao Zhang , Tianjiao Zhang , Haijian Zhao , Weiyan Zhou EMAIL logo and Chuanbao Zhang ORCID logo EMAIL logo
Published/Copyright: May 5, 2023

Abstract

Objectives

To find suitable external quality assessment (EQA) materials for serum C-peptide, we evaluated the commutability of five types of processed materials.

Methods

Seventy-four individual serum samples and 12 processed samples including three EQA samples currently in use, frozen human serum pools (FHSP), and three other kinds of processed samples were prepared by dissolving WHO International Standard Reagent for C-peptide (WHO ISR 13/146) in three different matrixes: 0.05 % bovine serum albumin, fetal bovine serum and human serum pools. Samples were analyzed using the isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method and six widely used immunoassays. The commutabilities of processed materials were assessed according to the difference in bias approach recommended by the IFCC. And the short- and long-term stability of FHSP samples at different temperatures were also evaluated.

Results

Out of the five kinds of processed materials, FHSP samples were commutable on most assays. In contrast, the EQA materials currently in use were only commutable on a few immunoassays. Additionally, processed materials derived from WHO ISR 13/146 were found to be un-commutable on over half of immunoassays. The FHSP samples could be stably stored at 4 and −20 °C for at least 16 days, and at −80 °C for at least 1 year, but at room temperature only for 12 h.

Conclusions

With clarified commutability and stability information, the human serum pool samples along with the developed ID-LC-MS/MS method could be used in the EQA program to promote the comparability among laboratories for C-peptide measurement in China.


Corresponding authors: Weiyan Zhou and Chuanbao Zhang, National Center for Clinical Laboratories, Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dongcheng District, Beijing 100730, P.R. China, Phone: +86 010 58115059, Fax: +86 010 65132968, E-mail: ,

Funding source: Beijing Natural Science Foundation

Award Identifier / Grant number: 7212087

Funding source: National Key Research and Development Program of China

Award Identifier / Grant number: 2022YFF0710301

Acknowledgments

The authors gratefully acknowledge the colleagues at West China Hospital, Sichuan University Department of Laboratory Medicine; Beijing Aerospace General Hospital Department of Laboratory Medicine; Snibe Diagnostic Co. Ltd. Shenzhen China; and Mindray Co. Ltd. Shenzhen China for their kind assistance in testing samples during this study.

  1. Research funding: Beijing Natural Science Foundation: No. 7212087. National Key Research and Development Program of China, Grant Number: No. 2022YFF0710301.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: The Ethics Committee of Beijing Hospital approved this study and exempted the need for obtaining informed consent (2018BJYYEC-019-01).

References

1. Zimmet, P, Alberti, KG, Magliano, DJ, Bennett, PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol 2016;12:616–22. https://doi.org/10.1038/nrendo.2016.105.Search in Google Scholar PubMed

2. Guariguata, L, Whiting, DR, Hambleton, I, Beagley, J, Linnenkamp, U, Shaw, JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137–49. https://doi.org/10.1016/j.diabres.2013.11.002.Search in Google Scholar PubMed

3. Leighton, E, Sainsbury, CA, Jones, GC. A practical review of C-peptide testing in diabetes. Diabetes Ther 2017;8:475–87. https://doi.org/10.1007/s13300-017-0265-4.Search in Google Scholar PubMed PubMed Central

4. Jones, AG, Hattersley, AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013;30:803–17. https://doi.org/10.1111/dme.12159.Search in Google Scholar PubMed PubMed Central

5. Zhou, W, Deng, Y, Zhao, H, Zhang, C. Current status of serum insulin and C-peptide measurement in clinical laboratories: experience from 94 laboratories in China. Ann Lab Med 2022;42:428–37. https://doi.org/10.3343/alm.2022.42.4.428.Search in Google Scholar PubMed PubMed Central

6. Zhang, S, Zeng, J, Zhang, C, Li, Y, Zhao, H, Cheng, F, et al.. Commutability of possible external quality assessment materials for cardiac troponin measurement. PLoS One 2014;9:e102046. https://doi.org/10.1371/journal.pone.0102046.Search in Google Scholar PubMed PubMed Central

7. Jones, GR. The role of EQA in harmonization in laboratory medicine – a global effort. Biochem Med 2017;27:23–9. https://doi.org/10.11613/bm.2017.004.Search in Google Scholar PubMed PubMed Central

8. Deng, Y, Zhang, C, Wang, J, Zeng, J, Zhang, J, Zhang, T, et al.. An accurate isotope dilution liquid chromatography-tandem mass spectrometry method for serum C-peptide and its use in harmonization in China. Ann Lab Med 2023;43:345–54. https://doi.org/10.3343/alm.2023.43.4.345.Search in Google Scholar PubMed PubMed Central

9. Miller, WG, Schimmel, H, Rej, R, Greenberg, N, Ceriotti, F, Burns, C, et al.. IFCC working group recommendations for assessing commutability part 1: general experimental design. Clin Chem 2018;64:447–54. https://doi.org/10.1373/clinchem.2017.277525.Search in Google Scholar PubMed PubMed Central

10. Nilsson, G, Budd, JR, Greenberg, N, Delatour, V, Rej, R, Panteghini, M, et al.. IFCC working group recommendations for assessing commutability part 2: using the difference in bias between a reference material and clinical samples. Clin Chem 2018;64:455–64. https://doi.org/10.1373/clinchem.2017.277541.Search in Google Scholar PubMed PubMed Central

11. CLSI. EP09-A3. Measurement procedure comparison and bias estimation using patient samples; approved guideline, 3rd ed. Wayne: Clinical and Laboratory Standards Institute; 2013.Search in Google Scholar

12. Little, RR, Wielgosz, RI, Josephs, R, Kinumi, T, Takatsu, A, Li, H, et al.. Implementing a reference measurement system for C-peptide: successes and lessons learned. Clin Chem 2017;63:1447–56. https://doi.org/10.1373/clinchem.2016.269274.Search in Google Scholar PubMed PubMed Central

13. Kinumi, T, Mizuno, R, Takatsu, A. Quantification of serum C-peptide by isotope-dilution liquid chromatography-tandem mass spectrometry: enhanced detection using chemical modification and immunoaffinity purification. J Chromatogr B Anal Technol Biomed Life Sci 2014;953–954:138–42. https://doi.org/10.1016/j.jchromb.2014.02.019.Search in Google Scholar PubMed

14. Kinumi, T, Goto, M, Eyama, S, Kato, M, Kasama, T, Takatsu, A. Development of SI-traceable C-peptide certified reference material NMIJ CRM 6901-a using isotope-dilution mass spectrometry-based amino acid analyses. Anal Bioanal Chem 2012;404:13–21. https://doi.org/10.1007/s00216-012-6097-1.Search in Google Scholar PubMed

15. Stoyanov, AV, Rohlfing, CL, Connolly, S, Roberts, ML, Nauser, CL, Little, RR. Use of cation exchange chromatography for human C-peptide isotope dilution – mass spectrometric assay. J Chromatogr A 2011;1218:9244–9. https://doi.org/10.1016/j.chroma.2011.10.080.Search in Google Scholar PubMed PubMed Central

16. Little, RR, Rohlfing, CL, Tennill, AL, Madsen, RW, Polonsky, KS, Myers, GL, et al.. Standardization of C-peptide measurements. Clin Chem 2008;54:1023–6. https://doi.org/10.1373/clinchem.2007.101287.Search in Google Scholar PubMed


Supplementary Material

This article contains supplementary material (https://doi.org/10.1515/cclm-2023-0215).


Received: 2023-02-27
Accepted: 2023-04-19
Published Online: 2023-05-05
Published in Print: 2023-08-28

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Developments in reference measurement systems for C-reactive protein and the importance of maintaining currently used clinical decision-making criteria
  4. Review
  5. Why C-reactive protein is one of the most requested tests in clinical laboratories?
  6. Mini Reviews
  7. C-reactive protein and clinical outcome in COVID-19 patients: the importance of harmonized measurements
  8. Current performance of C-reactive protein determination and derivation of quality specifications for its measurement uncertainty
  9. Opinion Papers
  10. Implementing metrological traceability of C-reactive protein measurements: consensus summary from the Joint Committee for Traceability in Laboratory Medicine Workshop
  11. Analytical performance specifications for the measurement uncertainty of 24,25-dihydroxyvitamin D examinations
  12. A new door to a different world: opportunities from the metaverse and the raise of meta-medical laboratories
  13. Guidelines and Recommendations
  14. Point-of-care testing performed by healthcare professionals outside the hospital setting: consensus based recommendations from the IFCC Committee on Point-of-Care Testing (IFCC C-POCT)
  15. General Clinical Chemistry and Laboratory Medicine
  16. Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer’s disease
  17. Long-term stability of thyroid peroxidase antibody (anti-TPO) in serum in the Danish General Suburban Population Study
  18. Exploration of suitable external quality assessment materials for serum C-peptide measurement
  19. Description and validation of an equilibrium dialysis ID-LC-MS/MS candidate reference measurement procedure for free thyroxine in human serum
  20. Evaluation of testosterone, estradiol and progesterone immunoassay calibrators by liquid chromatography mass spectrometry
  21. Lack of comparability of immunoassays for rheumatoid factor isotypes
  22. Validation of ELISA assays for the calculation of FLC indices for the diagnosis of intrathecal immunoglobulin synthesis
  23. First-trimester screening for Down syndrome using quadruple maternal biochemical markers
  24. Dipeptidyl peptidase 4 (DPP4) in fecal samples: validation of the extraction methodology and stability in short-term storage conditions
  25. Cardiovascular Diseases
  26. Interlaboratory variation for NT-proBNP among Swedish laboratories in an external quality program 2011–2021
  27. Infectious Diseases
  28. SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification
  29. Efficiency evaluation of a SARS-CoV-2 diagnostic strategy combining high throughput quantitative antigen immunoassay and real time PCR
  30. Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing
  31. Letters to the Editor
  32. Pooled analysis of laboratory-based SARS-CoV-2 antigen immunoassays
  33. Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing
  34. Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study
  35. Impact of switching total bilirubin assays on the classification of neonates at high risk for hyperbilirubinemia
  36. Discrepancies in PSA values among laboratories: the case of a traveling patient
  37. Measurement of amyloid-β 1–42 in cerebrospinal fluid: a comparison of the second generation Elecsys and INNOTEST
Downloaded on 7.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2023-0215/html
Scroll to top button